pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,050 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT967Endpoints741BioPharma Dive283BioSpace181Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5599Rare Disease1246Cardiology1051Hematology933Immunology917Vaccines812Pulmonology
  • Study shows drug development and reimbursement timelines align across four major markets
    Researchers published a cross‑sectional analysis in JAMA Health Forum examining how long it takes for a drug to move from the start of clinical trials to receiving reimbursement approval. The anal…
    raps · 18d agoNeutral↗ source
  • FDA panel backs compounding pharmacies to make two peptides, rejects third
    The U.S. Food and Drug Administration’s advisory committee met on Friday and issued recommendations on the manufacturing of certain peptide drugs by compounding pharmacies. Committee members voted…
    STAT · 18d agoRegulatoryNeutral↗ source
← prev
page 24 of 82
next →
63
fda recalls41
fda medwatch30
fda press25
776
Psychiatry & CNS688
Ophthalmology343
Endocrinology & Metabolism338
Pain335
Infectious Disease324
  • AstraZeneca says Wainua failure won’t alter M&A plans, stays on track for $80B 2030 goal
    AstraZeneca said during its Q2 earnings presentation that the late‑stage failure of the antisense therapy Wainua in ATTR‑cardiomyopathy does not derail its goal of reaching $80 billion in revenue b…
    BioSpace · 18d agoDealNeutral↗ source
  • Sarepta appoints Michael Severino as CEO to steer company beyond a turbulent year
    Sarepta Therapeutics announced that Michael Severino will become its chief executive officer, taking over from longtime leader Doug Ingram. Severino is slated to start on Tuesday and joins the com…
    Endpoints · 18d agoNeutral↗ source
  • Australia's TGA adopts 23 international scientific guidelines from EMA, ICH and FDA
    The Therapeutic Goods Administration (TGA) in Australia announced it has formally adopted 23 scientific guidelines. The guidelines come from the European Medicines Agency, the International Counci…
    raps · 18d agoRegulatoryNeutral↗ source
  • Legend Biotech CEO Ying Huang resigns, Carvykti head Max Gelman appointed interim chief
    Legend Biotech announced that its chief executive officer, Ying Huang, has stepped down after serving in the role since November 2020. Huang's resignation was reported on Friday, marking the end o…
    Endpoints · 18d agoNeutral↗ source
  • Nokia executive Pallavi Mahajan purchases 62,000 shares at $9.55 each
    Nokia reported an insider transaction by Pallavi Mahajan, a member of the senior management team. The filing indicates Mahajan bought 62,000 Nokia shares on July 24, 2026, at a price of $9.55 per…
    globenewswire health · 18d agoDealNeutral↗ source
  • FDA schedules advisory committee meetings for rejected Replimune melanoma drug and Capricor DMD cell therapy
    The FDA announced that it will hold two advisory committee meetings this week to revisit investigational therapies that were previously turned down. One meeting will consider Capricor Therapeutics'…
    BioSpace · 18d agoRegulatoryNeutral↗ source
  • Medical schools add hands-on nutrition programs while avoiding broader HHS priorities
    When students return to McGovern Medical School at UT Health Houston, they will take part in hands‑on nutrition experiences such as cooking demonstrations, tours of a holistic garden, and a culinar…
    STAT · 18d agoNeutral↗ source
  • E‑bikes and e‑scooters driving surge in severe pediatric injuries, say pediatric surgeons
    J. Todd R. Lawrence, a pediatric orthopedic surgeon, and Madison A. Kesler, a research associate at Children’s Hospital of Philadelphia, note a rapid rise in serious injuries among children using e…
    STAT · 18d agoNegative↗ source
  • Vaisala executive Vesa Pylvänäinen sells 1,582 shares at €56.92 each
    Vaisala Oyj disclosed a transaction by senior executive Vesa Pylvänäinen on July 23, 2026. He disposed of 1,582 ordinary shares of the company on the Nasdaq Helsinki market at an average price of…
    globenewswire health · 18d agoNeutral↗ source
  • Vaisala senior manager Vesa Pylvänäinen disposes 1,582 shares at €56.92 each
    Vaisala Corporation disclosed that senior manager Vesa Pylvänäinen sold a portion of his holdings. The disposal involved 1,582 shares of Vaisala A shares, with a volume‑weighted average price of €…
    globenewswire health · 18d agoNeutral↗ source
  • Nokia senior manager Pallavi Mahajan buys 62,000 shares at $9.55 each
    Nokia disclosed that senior manager Pallavi Mahajan filed a transaction notice under the EU Market Abuse Regulation. The notice, dated July 24, 2026, records Mahajan's purchase of 62,000 Nokia sha…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • Nokia senior manager Patrik Hammarén acquires 43,293 shares at €8.44 each
    Nokia Corporation disclosed that senior manager Patrik Hammarén purchased shares of the company. The acquisition was made on July 24, 2026 and involved a total of 43,293 shares at a unit price of…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • Midwives urge role in combating medical misinformation as patients reject blood based on vaccine myths
    Midwife Mara Evans, based in North Carolina and faculty at Georgetown University’s Berkley School of Nursing, writes about her experience in a Nevada delivery room. She describes the careful handli…
    STAT · 18d agoNeutral↗ source
  • Nokia board member Timo Ihamuotila reports share purchases across multiple markets on July 24, 2026
    Nokia Oyj disclosed an insider transaction by board member Timo Ihamuotila, filed under the market abuse regulation article 19 as an initial notification. The first purchase was made on the BEUP m…
    globenewswire health · 18d agoNeutral↗ source
  • Nokia board member Timo Ihamuotila purchases 33,700 shares at around €8.45 each
    On July 24, 2026, Timo Ihamuotila, a member of Nokia Corporation's board, executed multiple share purchases. He acquired 24,340 shares on the BEUP venue at a price of €8.4449 per share. Additiona…
    globenewswire health · 18d agoNeutral↗ source
  • Nokia executive Patrik Hammarén reports share purchase of 43,293 shares at €8.44 each
    Nokia Oyj disclosed a leadership transaction filed under market abuse regulation article 19. The filing lists senior executive Patrik Hammarén as the reporting person. The transaction involved a t…
    globenewswire health · 18d agoDealNeutral↗ source
  • Danske Bank reports share sales by APMH Invest under its buyback program
    On July 27, 2026, Danske Bank A/S filed a market-abuse regulation report detailing changes in share ownership. The filing shows that APMH Invest A/S sold shares of Danske Bank on a pro-rata basis…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • Danske Bank reports ongoing share sales by APMH Invest under its buy-back program
    Danske Bank A/S filed a notification on 27 July 2026 regarding transactions made by persons required to report under the EU Market Abuse Regulation. The bank’s share buy-back program continues, an…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • Upcoming Q2 earnings from Moderna, AstraZeneca, GSK and others highlighted in weekly pharma preview
    The Endpoints Weekly newsletter signals a busy earnings week for major pharmaceutical companies, with Q2 results slated from Moderna, AstraZeneca, GSK, Bristol Myers Squibb and several others. It…
    Endpoints · 20d agoEarningsNeutral↗ source
  • Biogen's Alzheimer's trial data ignites excitement and uncertainty over tau-targeting therapies
    Biogen recently shared results from a late-stage Alzheimer's trial that tested a therapy aimed at the tau protein, a key hallmark of the disease. The findings have sparked enthusiasm among researc…
    Endpoints · 21d agoNeutral↗ source
  • Amgen submits new analysis to FDA to defend continued availability of Tavneos
    Amgen has provided the FDA with a fresh analysis concerning its rare-disease therapy Tavneos, aiming to address the agency’s concerns. The company says the independent reevaluation supports the dr…
    Endpoints · 21d agoRegulatoryNeutral↗ source
  • Sanofi scraps most atopic dermatitis trials after amlitelimab fails to outperform standard care
    Sanofi announced it is halting all but one ongoing trial for amlitelimab, an OX40‑ligand antibody acquired through its $1.4 billion purchase of Kymab. The decision follows the Phase 3 COAST‑1 stud…
    BioSpace · 21d agoNegative readoutNegative↗ source
  • Scribe Therapeutics raises $129 million in rare early-stage IPO to fund epigenetic heart disease therapy
    Scribe Therapeutics, founded by Jennifer Doudna, completed an IPO raising nearly $129 million, selling 8.58 million shares at $15 each. It is the first gene‑editing company to go public in more tha…
    BioSpace · 21d agoDealPositive↗ source